119 related articles for article (PubMed ID: 29330049)
41. KIAA1718 is a histone demethylase that erases repressive histone methyl marks.
Yokoyama A; Okuno Y; Chikanishi T; Hashiba W; Sekine H; Fujiki R; Kato S
Genes Cells; 2010 Aug; 15(8):867-73. PubMed ID: 20629981
[TBL] [Abstract][Full Text] [Related]
42. NEDD4L represses prostate cancer cell proliferation via modulating PHF8 through the ubiquitin-proteasome pathway.
Feng R; Li Z; Ge G; Wang C; Jia Y; Ouyang J
Clin Transl Oncol; 2023 Jan; 25(1):243-255. PubMed ID: 36136271
[TBL] [Abstract][Full Text] [Related]
43. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
Konantz M; André MC; Ebinger M; Grauer M; Wang H; Grzywna S; Rothfuss OC; Lehle S; Kustikova OS; Salih HR; Handgretinger R; Fend F; Baum C; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
Leukemia; 2013 Jan; 27(1):56-65. PubMed ID: 22828445
[TBL] [Abstract][Full Text] [Related]
44. Features of the PHF8/KIAA1718 histone demethylase.
Suganuma T; Workman JL
Cell Res; 2010 Aug; 20(8):861-2. PubMed ID: 20644565
[No Abstract] [Full Text] [Related]
45. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
46. BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors.
Korfi K; Smith M; Swan J; Somervaille TC; Dhomen N; Marais R
Cell Death Dis; 2016 Apr; 7(4):e2177. PubMed ID: 27054332
[TBL] [Abstract][Full Text] [Related]
47. UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia.
Benyoucef A; Palii CG; Wang C; Porter CJ; Chu A; Dai F; Tremblay V; Rakopoulos P; Singh K; Huang S; Pflumio F; Hébert J; Couture JF; Perkins TJ; Ge K; Dilworth FJ; Brand M
Genes Dev; 2016 Mar; 30(5):508-21. PubMed ID: 26944678
[TBL] [Abstract][Full Text] [Related]
48. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
49. Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.
Sakamoto T; Ozaki K; Fujio K; Kajikawa SH; Uesato S; Watanabe K; Tanimura S; Koji T; Kohno M
Biochem Biophys Res Commun; 2013 Apr; 433(4):456-62. PubMed ID: 23501104
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
Felipe Fumero E; Walter C; Frenz JM; Seifert F; Alla V; Hennig T; Angenendt L; Hartmann W; Wolf S; Serve H; Oellerich T; Lenz G; Müller-Tidow C; Schliemann C; Huber O; Dugas M; Mann M; Jayavelu AK; Mikesch JH; Arteaga MF
Blood; 2024 May; 143(22):2284-2299. PubMed ID: 38457355
[TBL] [Abstract][Full Text] [Related]
51. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
52. PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation.
Feng W; Yonezawa M; Ye J; Jenuwein T; Grummt I
Nat Struct Mol Biol; 2010 Apr; 17(4):445-50. PubMed ID: 20208542
[TBL] [Abstract][Full Text] [Related]
53. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
54. A PHF8 homolog in C. elegans promotes DNA repair via homologous recombination.
Lee C; Hong S; Lee MH; Koo HS
PLoS One; 2015; 10(4):e0123865. PubMed ID: 25853498
[TBL] [Abstract][Full Text] [Related]
55. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
[TBL] [Abstract][Full Text] [Related]
56. The histone demethylase PHF8 is essential for cytoskeleton dynamics.
Asensio-Juan E; Gallego C; Martínez-Balbás MA
Nucleic Acids Res; 2012 Oct; 40(19):9429-40. PubMed ID: 22850744
[TBL] [Abstract][Full Text] [Related]
57. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
[TBL] [Abstract][Full Text] [Related]
58. WDR5 high expression and its effect on tumorigenesis in leukemia.
Ge Z; Song EJ; Kawasawa YI; Li J; Dovat S; Song C
Oncotarget; 2016 Jun; 7(25):37740-37754. PubMed ID: 27192115
[TBL] [Abstract][Full Text] [Related]
59. Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.
George AA; Paz H; Fei F; Kirzner J; Kim YM; Heisterkamp N; Abdel-Azim H
PLoS One; 2015; 10(9):e0137917. PubMed ID: 26360058
[TBL] [Abstract][Full Text] [Related]
60. LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia.
Chong PS; Zhou J; Cheong LL; Liu SC; Qian J; Guo T; Sze SK; Zeng Q; Chng WJ
Cancer Res; 2014 Jun; 74(11):3043-53. PubMed ID: 24686170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
